NASDAQ:ANIK - Nasdaq - US0352551081 - Common Stock - Currency: USD
11.15
-0.11 (-0.98%)
The current stock price of ANIK is 11.15 USD. In the past month the price decreased by -22.89%. In the past year, price decreased by -56.53%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 328.74B | ||
AMGN | AMGEN INC | 13.88 | 154.96B | ||
GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
ARGX | ARGENX SE - ADR | 99.7 | 35.00B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.29 | 26.55B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
NTRA | NATERA INC | N/A | 21.54B | ||
BIIB | BIOGEN INC | 8.2 | 19.02B | ||
UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 288 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
ANIKA THERAPEUTICS INC
32 Wiggins Ave
Bedford MASSACHUSETTS 01730 US
CEO: Cheryl R. Blanchard
Employees: 288
Phone: 17814579000
The current stock price of ANIK is 11.15 USD. The price decreased by -0.98% in the last trading session.
The exchange symbol of ANIKA THERAPEUTICS INC is ANIK and it is listed on the Nasdaq exchange.
ANIK stock is listed on the Nasdaq exchange.
9 analysts have analysed ANIK and the average price target is 23.46 USD. This implies a price increase of 110.4% is expected in the next year compared to the current price of 11.15. Check the ANIKA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ANIKA THERAPEUTICS INC (ANIK) has a market capitalization of 159.89M USD. This makes ANIK a Micro Cap stock.
ANIKA THERAPEUTICS INC (ANIK) currently has 288 employees.
ANIKA THERAPEUTICS INC (ANIK) has a support level at 11.14 and a resistance level at 13.6. Check the full technical report for a detailed analysis of ANIK support and resistance levels.
The Revenue of ANIKA THERAPEUTICS INC (ANIK) is expected to decline by -26.79% in the next year. Check the estimates tab for more information on the ANIK EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANIK does not pay a dividend.
ANIKA THERAPEUTICS INC (ANIK) will report earnings on 2025-08-06, after the market close.
ANIKA THERAPEUTICS INC (ANIK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.1).
The outstanding short interest for ANIKA THERAPEUTICS INC (ANIK) is 2.92% of its float. Check the ownership tab for more information on the ANIK short interest.
ChartMill assigns a fundamental rating of 4 / 10 to ANIK. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ANIK reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS increased by 60% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.77% | ||
ROE | -38.24% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 87% to ANIK. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 58.61% and a revenue growth -26.79% for ANIK